EA202092106A3 - MODIFIED FGF-21 POLYPEPTIDES AND THEIR APPLICATION - Google Patents

MODIFIED FGF-21 POLYPEPTIDES AND THEIR APPLICATION

Info

Publication number
EA202092106A3
EA202092106A3 EA202092106A EA202092106A EA202092106A3 EA 202092106 A3 EA202092106 A3 EA 202092106A3 EA 202092106 A EA202092106 A EA 202092106A EA 202092106 A EA202092106 A EA 202092106A EA 202092106 A3 EA202092106 A3 EA 202092106A3
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptides
modified fgf
application
optionally
modified
Prior art date
Application number
EA202092106A
Other languages
Russian (ru)
Other versions
EA202092106A2 (en
Inventor
Пол Е. Морин
Дэниэл Кохен
Ранжан Мухерджи
Тимоти П. Рейлли
Роуз С. Кристиан
Даса Липовсек
Рэй Камфаузен
Джон Крупински
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA202092106A2 publication Critical patent/EA202092106A2/en
Publication of EA202092106A3 publication Critical patent/EA202092106A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]

Abstract

Предусмотрены модифицированные полипептиды FGF-21 и их применения, например, для лечения связанных с фиброзом заболеваний. Раскрыты модифицированные полипептиды FGF-21, которые содержат внутреннюю делецию и необязательно замещающий пептид, необязательно модифицированный, по меньшей мере, посредством одной неканонической аминокислоты и/или необязательно слитый с партнером по слиянию.Provided are the modified FGF-21 polypeptides and their uses, for example, in the treatment of fibrosis-related diseases. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and an optionally substitute peptide, optionally modified by at least one non-canonical amino acid and / or optionally fused to a fusion partner.

EA202092106A 2015-04-01 2015-10-23 MODIFIED FGF-21 POLYPEPTIDES AND THEIR APPLICATION EA202092106A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562141383P 2015-04-01 2015-04-01

Publications (2)

Publication Number Publication Date
EA202092106A2 EA202092106A2 (en) 2021-06-30
EA202092106A3 true EA202092106A3 (en) 2021-09-30

Family

ID=76807403

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092106A EA202092106A3 (en) 2015-04-01 2015-10-23 MODIFIED FGF-21 POLYPEPTIDES AND THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA202092106A3 (en)

Also Published As

Publication number Publication date
EA202092106A2 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
EA201790895A1 (en) MODIFIED FGF-21 POLYPEPTIDES AND THEIR APPLICATION
MX2017006866A (en) Fusion partners for peptide production.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
EA201591661A1 (en) PEPTIDES AND COMPOSITIONS FOR TREATING DAMAGE TO JOINTS
MX2016008539A (en) Fc-region variants with modified fcrn- and maintained protein a-binding properties.
EA201891420A1 (en) ANTIBODIES TO MYOSTATIN, POLYPEPTIDES, CONTAINING OPTIONS OF FC-REGIONS, AND METHODS OF THEIR APPLICATION
EA201990017A1 (en) ANTIBODIES TO MYOSTATIN AND WAYS OF THEIR APPLICATION
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
EA201691795A1 (en) A METHOD FOR IMPROVING THE SOLUBILITY OF PROTEIN AND PEPTIDE AT THE EXPENSE OF USING A BINDING WITH THE FRAGMENT OF IMMUNOGLOBULIN
BR112016007328A2 (en) epinephrine-based ophthalmic compositions for intraocular administration and methods for making same
EA202090084A1 (en) NEW THERAPEUTIC ENZYME Fusion PROTEIN AND ITS APPLICATION
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
EA202091239A1 (en) FUSION PROTEIN BASED ON A THERAPEUTIC ENZYME WITH A NEW STRUCTURE AND ITS APPLICATION
UA117493C2 (en) HYBRID CONSTRUCTION INCLUDING AN ANTIGEN-SPECIFIC FRAGMENT SPECIFIC TO SERUM ALBUMIN AND AN EFFECTIVE COMPONENT AND METHODS
EA201501028A1 (en) CONSTRUCTIONS OF MITOCHONDRIAL PROTEINS AND THEIR APPLICATION
PH12015500890A1 (en) Vaccine for preventing porcine edema disease
PE20170257A1 (en) UTI FUSION PROTEINS
CL2020000733A1 (en) Fusion protein comprising a portion of fgf-18.
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
UY36262A (en) ANTIBODIES ANTI PROTEIN SIMILAR TO ANGIOPOYETINA 4 AND METHODS OF USE
PH12017500742A1 (en) Statherin peptides
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2018003445A (en) Expression of fc-containing proteins.
EA202090143A1 (en) PHARMACEUTALLY ACCEPTABLE SALTS OF POLYPEPTIDES AND THEIR APPLICATION
EA202092106A2 (en) MODIFIED FGF-21 POLYPEPTIDES AND THEIR APPLICATION